This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

ICON And Fountain Medical Development (FMD) Announce Opening Of Laboratory Facility In China

ICON Central Laboratories - a division of ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries – today announced the opening of a new laboratory facility in Tianjin, China, in partnership with Fountain Medical Development Ltd (FMD). It is the third ICON laboratory in the Asia-Pacific region.

ICON Central Laboratories China offers 3000 square feet of laboratory space and is located 70 miles from Beijing in Tianjin – one of China’s most accessible and technologically advanced cities. It will deliver site support services to clinical investigators throughout China and offers overall benefits including shorter shipping distances between clinical sites and existing laboratory testing facilities which expedites study completion.

The facility will offer a comprehensive menu of testing services that includes: chemistry, haematology, coagulation, immunology and other testing services to meet study-specific requirements. The laboratory received CAP (College of American Pathologists) accreditation in May 2010 and is also NGSP Level I Certified.

Commenting on the announcement, Tom O’Leary, President - ICON Central Laboratories, said: “Our alliance with Fountain Medical Development (FMD) and the launch of this new facility underlines our commitment to satisfying our clients’ growing demand for quality central laboratory services in the Asia-Pacific region.”

Dan Zheng, CEO, FMD, added: “Partnering with ICON Central Laboratories gives the FMD team access to the resources, systems and infrastructure of a large international organisation involved in the management of both large global trials and localised studies. In return, our local knowledge and experience will be utilised by ICON as they work to provide clients with a faster and more cost efficient service.”

ICON has been operational in the Asia-Pacific region for over 10 years, where it already employs over 800 staff, with existing laboratory facilities situated in Bangalore and Singapore.

Notes to Editors:

About ICON plc:

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently employs over 7,300 employees, operating from 71 locations in 39 countries.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ICLR $69.01 0.00%
AAPL $128.46 0.00%
FB $78.97 0.00%
GOOG $558.40 0.00%
TSLA $203.34 0.00%

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs